CDK12 and breast cancer: The reversion of the poor prognostic outcome of CDK12HIGH patients, in response to MTX-based antimetabolite therapy, to a more favorable disease course vis a vis the absence of any significant effect of this treatment in CDK12LOW or CDK12NULL patients reveals a typical oncogene addiction-like therapeutic vulnerability in CDK12-overexpressing breast cancers.